MBIO - Mustang Bio commences study of CAR T therapy in blood cancers

The first participant has been dosed in a 126-subject Phase 1/2 clinical trial evaluating Mustang Bio's (MBIO) CAR T therapy MB-102 in patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukemia and high-risk myelodysplastic syndromes.The first phase will assess safety and determine the maximum tolerated dose for the second phase which may have as many as three arms.The primary endpoint of the Phase 2 will be the response rate at day 28 post infusion. Secondary endpoints include duration of response, progression-free survival, overall survival and incidence of treatment-emergent adverse events, which will be followed for up to three years.The estimated primary completion date is March 2023.

For further details see:

Mustang Bio commences study of CAR T therapy in blood cancers